Alimera Sciences — Technical Presentation (May 2011)
15 slides from Alimera Sciences's technical presentation, May 5, 2011
Slide 1: Duration of DME Subgroup Analysis of the FAME Study
Alimera Sciences, Inc. Duration of DME Subgroup Analysisof the FAME StudyWebcastMay 5, 2011 1
Slide 2: Percentage of Patients With ≥15-Letter Improvement Over Baseline, FAME A+B
Time (Months) Patients (%) P = .018 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A+B, Full Population Primary Readout P = .002
Slide 3: Subgroup
Subgroup Ideal subgroup should meet the following: Statistically significant VA results at month 24 and 36 Greater benefit to risk ratio Identifiable prior to administration of ILUVIEN
Slide 4: Baseline Demographics and Disease Characteristics, FAME A + B
Baseline Demographics and Disease Characteristics, FAME A + B, DME ^ 3 Year Subgroup, Full Population FAME A + B, DME ^ 3 Year Subgroup, Full Population FAME A + B, DME ^ 3 Year Subgroup, Full Population
Slide 5: FAME A Duration of DME Subgroup Analysis
FAME A Duration of DME Subgroup Analysis
Slide 6: .010 A, DME ^ = .004
Time (Months) Patients (%) P = .010 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A, DME ^ 3 Year Subgroup Primary Readout P = .004
Slide 7: .441 A, DME < = .836
Time (Months) Patients (%) P = .441 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A, DME < 3 Year Subgroup Primary Readout P = .836
Slide 8: FAME B Duration of DME Subgroup Analysis
FAME B Duration of DME Subgroup Analysis
Slide 9: .004 B, DME ^ = .006
Time (Months) Patients (%) P = .004 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME B, DME ^ 3 Year Subgroup Primary Readout P = .006
Slide 10: .424 B, DME < = .886
Time (Months) Patients (%) P = .424 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME B, DME < 3 Year Subgroup Primary Readout P = .886
Slide 11: FAME A + B Duration of DME Subgroup Analysis
FAME A + B Duration of DME Subgroup Analysis
Slide 12: < .001 A + B, DME ^ < .001
Time (Months) Patients (%) P < .001 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A + B, DME ^ 3 Year Subgroup Primary Readout P < .001
Slide 13: .275 A + B, DME < = .984
Time (Months) Patients (%) P = .275 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A + B, DME < 3 Year Subgroup Primary Readout P = .984
Slide 14: Safety Profile: Cataract-Related and IOP-Related Events
Cataract-Related Events Cataract-Related Events DME ^ 3 Year Subgroup DME ^ 3 Year Subgroup Full Population Full Population Patients, %(Study Eye) Control(n = 112) 0.2 µg/d FAc (n = 209) Control(n = 112) 0.2 µg/d FAc (n = 209) IOP > 30 mm Hgb 5.4 14.8 4.3 18.4 Trabeculoplasty 0.0 1.9 0.0 1.3 Incisio
Slide 15: Duration of DME Subgroup Analysis of the FAME Study
Alimera Sciences, Inc. Duration of DME Subgroup Analysisof the FAME StudyWebcastMay 5, 2011 1